Home › Research › Getting a diagnosis
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis
Viola KL, Klein WL.. Acta neuropathologica, 2015-01-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Key experiments using fibril-free AβO solutions demonstrated that while Aβ is essential for memory loss, the fibrillar Aβ in amyloid deposits is not the agent. Overall, current evidence indicates that Aβ oligomers provide a substantive molecular basis for the cause, treatment and diagnosis of Alzheimer's disease.
What this study adds
Evidence grade: Low
This is a narrative review. This review argues that amyloid β oligomers, rather than fibrillar amyloid in deposits, provide a molecular basis for the cause, treatment, and diagnosis of Alzheimer's disease. It is a summary of evidence and does not report a proven treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Viola, K. L., & Klein, W. L. (2015). Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta neuropathologica. https://doi.org/10.1007/s00401-015-1386-3
Vancouver
Viola KL, Klein WL. Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta neuropathologica. 2015. doi:10.1007/s00401-015-1386-3. PMID: 25604547.
BibTeX
@article{viola2015-25604547,
author = {Viola, K. L. and Klein, W. L.},
title = {{Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis}},
journal = {Acta neuropathologica},
year = {2015},
doi = {10.1007/s00401-015-1386-3},
pmid = {25604547},
url = {https://doi.org/10.1007/s00401-015-1386-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Key experiments using fibril-free AβO solutions demonstrated that while Aβ is essential for memory loss, the fibrillar Aβ in amyloid deposits is not the agent.
- Overall, current evidence indicates that Aβ oligomers provide a substantive molecular basis for the cause, treatment and diagnosis of Alzheimer's disease.
Why it matters
This review argues that amyloid β oligomers, rather than fibrillar amyloid in deposits, provide a molecular basis for the cause, treatment, and diagnosis of Alzheimer's disease. It is a summary of evidence and does not report a proven treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Evidence strengthLow
How this study scored 52/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Acta neuropathologica) |
| Journal's citation record | 3 / 4 | Acta Neuropathologica: journal h-index 287 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 628 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 48.3 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 5 / 6 | Cited 35.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 3 / 4 | Cited 140 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author William L. Klein: h-index 79 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Northwestern University: institution h-index 1,592 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25604547) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Getting a diagnosis from nearby years
Also in Getting a diagnosis
141 studies in the library are filed under Getting a diagnosis with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Getting a diagnosis hub.